Putylone
Designer drug of the cathinone class
From Wikipedia, the free encyclopedia
Putylone (also known as β-keto-1,3-benzodioxolyl-N-propyldioxybutanamine, bk-PBDB, and N-propylbutylone) is a stimulant and empathogen compound detected in 2023,[1] around the time of a ban on the related compound eutylone.
ATC code
- None
Legal status
- BR: Class F2 (Prohibited psychotropics)
- CA: Schedule I
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class B
- US: Schedule I
| |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H19NO3 |
| Molar mass | 249.310 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Legal status
The specific legal status of putylone has not yet been addressed by any agency or government.
Putylone is likely considered illegal in jurisdictions where similar analogues or psychoactive substances bans are in place, such as in the US, UK, and Ireland.